Compare · CSTL vs UNH
CSTL vs UNH
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $365.02B, about 353.5x CSTL ($1.03B).
- UNH has been more active in the news (28 items in the past 4 weeks vs 12 for CSTL).
- UNH has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- UnitedHealth Group Incorporated
- Price
- -
- -
- Market cap
- $1.03B
- $365.02B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 12
- 28
- Recent ratings
- 6
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest CSTL
- Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
- SEC Form 4 filed by Castle Biosciences Inc.
- ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
- SEC Form 4 filed by Castle Biosciences Inc.
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 4 filed by Castle Biosciences Inc.
- Chief Commercial Officer Juvenal Tobin W sold $232,128 worth of shares (6,577 units at $35.29) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 52,007 units (SEC Form 4)
- Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
- New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
- New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Latest UNH
- SEC Form 8-K filed by UnitedHealth Group Incorporated
- UnitedHealth Group Reports Third Quarter 2026 Results
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated
- SEC Form 4 filed by UnitedHealth Group Incorporated